Page 134 - 202004
P. 134
群中的 PK 参数不尽相同,尽管部分研究已经给出了具 of vancomycin in postoperative neurosurgical patients and
体的给药方案推荐,但考虑到研究人群的样本量小、种 the application in dosing recommendation[J]. J Pharm
族差异等因素,需要开展更多、更广泛的大样本研究来 Sci,2016,105(11):3425-3431.
予以验证,以期为万古霉素的临床应用提供科学参考。 [15] LI X,SUN S,LING X,et al. Plasma and cerebrospinal flu-
参考文献 id populationpharmacokinetics of vancomycin in postoper-
[ 1 ] 吴委.万古霉素群体药动学及个体化给药研究[D].福州: ative neurosurgical patients after combined intravenous
福建医科大学,2013. and intraventricular administration[J]. Eur J Clin Pharma-
[ 2 ] 芮建中,张震,李金恒.群体药代动力学/群体药效动力学 col,2017,73(12):1599-1607.
原理及研究方法[J].医学研究生学报,2005,18(3): [16] LIN WW,WU W,JIAO Z,et al. Population pharmacoki-
246-249. netics of vancomycinin adult Chinese patients with post-
[ 3 ] 林忠,陈敏方,崔可,等.中国成年感染患者万古霉素群体 craniotomy meningitis and its application in individu-
药动学研究[J].中国现代应用药学,2017,34(1):105- alised dosage regimens[J]. Eur J Clin Pharmacol,2016,72
110. (1):29-37.
[ 4 ] 陈冰,杨婉花,张伟霞,等.中国成年患者万古霉素群体药 [17] 曾英彤,黄碧瑜,邱榆淇,等.老年透析ICU患者万古霉素
动学研究[J].药学与临床研究,2013,21(6):605-609. 群体药动学研究[C]//2017年广东省药师周大会论文集,
[ 5 ] DENG CH,LIU TT,ZHOU TY,et al. Initial dosage regi- 2017:949-964.
mens of vancomycin for Chinese adult patients based on [18] ECONOMOU CJP,KIELSTEIN JT,CZOCK D,et al.
population pharmacokinetic analysis[J]. Int J Clin Pharm Population pharmacokinetics of vancomycin in critically
Ther,2013,51(5):407-415. ill patients receiving prolonged intermittent renal replace-
[ 6 ] YASUHAR M,IGA T,ZENDA H,et al. Population phar- ment therapy[J]. Int J Antimicrob Agents,2018,52(2):
macokinetics of vancomycin in Japanese adult patients[J]. 151-157.
Ther Drug Monit,1998,20(2):139-148. [19] ESCOBAR L,ANDRESEN M,DOWNEY P,et al. Popu-
[ 7 ] YAMAMOTO M,KUZUYA T,BABA H,et al. Popula- lation pharmacokinetics and dose simulation of vancomy-
tion pharmacokinetic analysis of vancomycin in patients cin in critically ill patients during high-volume haemofil-
with grampositivein fections and the influence of infec- tration[J]. Int J Antimicrob Agents,2014,44(2):163-167.
tious disease type[J]. J Clin Pharm Ther,2009,34(4): [20] DONADELLO K,ROBERTS JA,CRISTALLINIS,et al.
473-483. Vancomycin population pharmacokinetics during extracor-
[ 8 ] PURWONUGROHO TA,CHULAVATNATO LS,PREE- poreal membrane oxygenation therapy:a matched cohort
CHAGOON Y,et al. Population pharmacokinetics of van- study[J]. Crit Care,2014,18(6):1-10.
comycin in Thai patients[J]. Scientific World J,2012. DOI: [21] 杨薇,贺蓓,邓晨辉.下呼吸道感染重症患者万古霉素群
10.1100/2012/762649. 体药代动力学研究[J].中华结核和呼吸杂志,2017,40
[ 9 ] 杨平,刘亚欧,时正媛,等.万古霉素在重症监护患者的群 (3):205-209.
体药代动力学模型建立与验证[J].中国临床药理学杂
[22] ABRAHAM J,SINOLLAREDDY MG,ROBERTS MS,
志,2018,34(6):656-659.
et al. Plasma and interstitial fluid population pharmacoki-
[10] REVILLA N,MARTÍN-SUÁREZ A,PÉREZ MP,et al.
netics of vancomycin in critically patients with sepsis[J].
Vancomycin dosing assessment in intensive care unit pa-
Int J Antimicrob Agents,2018,53(2):137-142.
tients based on a population pharmacokinetic/pharmacody-
[23] BUELGA DS,DEL MAR FERNANDEZDE GM,HER-
namicsimulation[J]. Br J Clin Pharmacol,2010,70(2):
RERA EV,et al. Population pharmacokinetic analysis of
201-212.
vancomycin in patients with hematological malignan-
[11] TURNER RB,KOJIRO K,WON R,et al. Prospective
cies[J]. Antimicrob Agents Chemother,2006,49(12):
evaluation of vancomycin pharmacokinetics in a heteroge-
4934-4941.
neous critically-ill population[J]. Diagn Microbiol Infect
[24] MULLA H,POOBONI S. Population pharmacokinetics of
Dis,2018,92(4):346-351.
vancomycin in patients receiving extracorporeal mem-
[12] LIOPIS-SALVIA P,JIMÉNEZ-TORRES NV. Population
brane oxygenation[J]. Br J Clin Pharmacol,2005,60(3):
pharmacokinetic parameters of vancomycin in critically ill
265-275.
patients[J]. J Clin Pharm Ther,2006,31(5):447-454.
[13] LI X,WU Y,SUN S,et al. Population pharmacokinetics [25] AARONS L. Population pharmacokinetics:theory and pra-
of vancomycin in postoperative neurosurgical patients[J]. J ctice[J]. Br J Clin Pharmacol,2012,32(6):669-670.
Pharm Sci,2015,104(11):3960-3967. (收稿日期:2019-04-11 修回日期:2020-01-09)
(编辑:孙 冰)
[14] LI X,WU Y,SUN S,et al. Population pharmacokinetics
·508 · China Pharmacy 2020 Vol. 31 No. 4 中国药房 2020年第31卷第4期